14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
INSM vs MRNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Moderna, Inc. (MRNA) captures the overall head-to-head institutional edge over Insmed, Inc. (INSM) on higher Unified Composite conviction (40.3/100 SELL vs. 39.6/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, R&D & Supply-Chain Moat), while INSM wins 4–2 across the 6-pillar growth and valuation breakdown. INSM trades at $141.33 (N/M Forward P/E, -41.7% operating margin) versus MRNA at $195.00 (23.0x Forward P/E, -80.8% operating margin).
Growth vs. Quality Trade-Off: MRNA earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. INSM 39.6/100 SELL) and 2.23β · 78% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both INSM (39.6/100 SELL) and MRNA (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment38.8% of Rev ($980M)
90D Engineering Disclosures0 Published · mRNA Therapeutics
Investor FAQ INSM vs MRNA Key Questions & Quantitative Answers
As of Nov 20, 2026, Moderna, Inc. (MRNA) captures the overall head-to-head institutional edge over Insmed, Inc. (INSM) on higher Unified Composite conviction (40.3/100 SELL vs. 39.6/100 SELL) after splitting the core matrix 7–3 (led by Valuation Multiples, R&D & Supply-Chain Moat), while INSM wins 4–2 across the 6-pillar growth and valuation breakdown. INSM trades at $141.33 (N/M Forward P/E, -41.7% operating margin) versus MRNA at $195.00 (23.0x Forward P/E, -80.8% operating margin). Growth vs. Quality Trade-Off: MRNA earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. INSM 39.6/100 SELL) and 2.23β · 78% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both INSM (39.6/100 SELL) and MRNA (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
INSM leads the Growth & Scale pillar: INSM posts +268.4% YoY revenue growth and +0.0% YoY earnings growth on $1.52B TTM revenue (84.4% gross margin, -41.7% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INSM cumulative revenue shifted +6000.0% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, INSM deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.
MRNA screens cheaper on headline valuation multiples. INSM trades at N/M Forward P/E, 106.4x Trailing P/E, 1.09x PEG, and 21.0x EV/Revenue (-41.3% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INSM (-72.5% ROE) versus MRNA (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, INSM carries 50.7% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.37β · 91% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.